i
Epidemiology of echinocandin resistance in Candida
-
Sep 21 2014
Source: Curr Fungal Infect Rep. 8(4):243-248.
[PDF-307.70 KB]
Details:
-
Alternative Title:Curr Fungal Infect Rep
-
Personal Author:
-
Description:Echinocandins are the newest antifungal agents approved for use in treating | infections in the US. They act by interfering with 1,3-β-D-glucan synthase and therefore disrupt cell wall production and lead to | cell death. There is no intrinsic resistance to echinocandins among | species, and isolates from historic collections archived before the release of the echinocandins show no resistance. Resistance to the echinocandins remains low among most | species and ranges overall from 0-1%. Among isolates of |, the proportion of resistant isolates is higher and has been reported to be as high as 13.5% in at least one hospital. Antifungal resistance is due to specific amino acid mutations in the Fksp subunit(s) of the 1,3-β-D-glucan synthase protein which are localized to one of two hotspots. These mutations are being recognized in isolates from patients who have failed echinocandin therapy, and often lead to a poor outcome. While the future looks bright for the echinocandins against most | species, | remains a species of concern and resistance rates of | to the echinocandins should be monitored closely.
-
Subject:
-
Pubmed ID:29780439
-
Pubmed Central ID:PMC5956517
-
Document Type:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
Email
CDC-INFO
